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Supplementary Note 1. Background on fibrinogen
Fibrinogen is an important biomarker, and its plasma concentration has clinical value. It is an acute phase reactant, a coagulation factor, and the principal element of blood clots. The fibrinogen protein is synthesized in the liver and is one of the most abundant proteins in plasma with normal concentrations 1 of 1.75-4.3 g L -1
. Increased fibrinogen levels can indicate inflammatory state, or pregnancy, whereas decreased levels can result from hepatic synthesis dysfunction, thrombosis, genetic diseases such as afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia, and disseminated intravascular coagulation 1 . The latter is associated with severe clinical conditions such as sepsis, trauma, cancer, obstetrical complications, vascular disorder, presence of toxins, and immunologic disorder 2 .
The coagulation cascade associated with the wound healing response can be initiated by the activation of either one of two possible pathways, extrinsic and intrinsic, which converge to a common pathway, in which prothrombin is converted into thrombin which hydrolyzes fibrinogen, forming insoluble fibrin monomers that polymerize to form a thrombus 3 . The extrinsic pathway is initiated by the release of tissue factors through a broken blood vessel wall, whereas the intrinsic pathway is initiated by contact with negatively charged surfaces within a damaged vessel, such as exposed subendothelial tissue or collagen 4 . Direct methods for determining fibrinogen concentration in blood are based on immunological assays, such as enzyme-linked immunosorbent assays (ELISA), radial immunodiffusion (Mancini method), and gel electrophoresis followed by immunoblotting 5 . Supplementary functional assays for estimating the amount of active clottable fibrinogen such as thrombin time (TT), prothrombin time (PT), and partial thromboplastin time (PTT), involve the addition of an activator of one of the coagulation pathways to plasma samples, followed by a measurement of the clotting time 1, 5 . Thrombin time tests the activation of fibrinogen to fibrin by adding high concentration of thrombin, prothrombin time screens the extrinsic pathway by adding tissue factors (thromboplastin) that are released upon vessel wall damage, and partial thromboplastin time screens the intrinsic pathway by adding ground glass to mimic the charged surface contact. Normal times are 20 -30 sec for TT, 11-14 sec for PT, and 22-35 sec for PTT 6 .
The fibrinogen protein is constructed by three pairs of mostly alpha-helix polypeptide chains (Aα, Bβ, and γ) linked by disulfide bonds. Its structure appears as three-nodules, one in the middle (Edomain), and two at each of the ends (D-domains), which are connected by helical chains 7, 8 . The total length of the fibrinogen molecule ranges between 45 nm -50 nm, the diameter of the middle and outer nodules are 5 nm and 6.5 nm, respectively, and the width of the interconnection helical coil is of the order of 1.5 nm 7 . The distribution of the possible angles between the two helical chains originating at the middle nodule was found to be bimodal with peaks around 157 and 106 degrees 9 , granting the fibrinogen an elongated structure with high aspect ratio. 20 , human chorionic gonadotropin (hCG) 21 , and C-reactive protein (CRP) 22 .
The references indicate the corresponding protein data bank (PDB) files used for the visualization of the hydrophobicity maps.
